Dovitinib is a potent, orally active small-molecule multi-kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Primarily investigated for the treatment… Read more
Dovitinib is a potent, orally active small-molecule multi-kinase inhibitor that targets multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Primarily investigated for the treatment of various malignancies, such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, it requires precise analytical support throughout drug development. This category provides essential reference standards, including the active pharmaceutical ingredient, related impurities like N-desmethyl dovitinib, and stable isotope labelled compounds such as deuterated isotopologues. These high-quality materials are critical for laboratories conducting rigorous impurity profiling, method validation, and routine quality control studies. By utilizing these characterized standards, researchers can ensure accurate quantification and regulatory compliance during the development and stability testing of this therapeutic agent.